Interesting stock tried to find it on Canadian Stock exchange but couldn't it only trades in US considering it is stationed here in Ontario. BNN has a clip today on what the company is doing and what they are doing. I do not own the stock as I haven't seen it trade yet as I am considering it. I do see it has done a stock split recently. The volume seems very low. I am actually surprised this stock is trading a bit low considering what it is doing with Merck and there maybe bio-tech companies that might be interested when they can approve their machine to test for heart attacks. I can also post for the posters what CNGH does and it's specs.JMHO
BNN Afterhours
5:30 PM Dr. Yahia Gawad
CEO
Cardiogenics
Focus: Heart attacks remain a leading cause of death and a big strain on the health care system. BNN sits down with Dr. Yahia Gawad, CEO, Cardiogenics a Canadian biotech looking to change that with a non-invasive heart attack test that would reduce wait times from over two hours to ten minutes.
Coming Up:
After Hours : August 16, 2010 : Advanced Heart Attack Diagnostics [08-16-10 5:20 PM]
One Canadian company is developing a technology to reduce the heart attack diagnostic process from an average of 2.8 hours to 15 minutes. BNN interviews Dr. Yahia Gawad, CEO, Cardiogenics.
Quote DetailsPrintable VersionShow MeOpen 0.42 P/E Ratio (TTM) --
Last Bid/Size 0.40 / 50 EPS (TTM) -0.83
Last Ask/Size 10.00 / 5 Next Earnings --
Previous Close 0.42 Beta 1.00
Volume 15,000 Last Dividend --
Average Volume 75,979 Dividend Yield 0.00%
Day High 0.42 Ex-Dividend Date --
Day Low 0.42 Shares Outstanding 24.6M
52 Week High 7.40 # of Floating Shares 49.61964M
52 Week Low 0.12 Short Interest as % of Float
52 Week Range Market Cap Sector/Industry
0.12 - 7.40 10.3M Technology/Scientific & Technical Instr.
Though CGNH has outperformed its Scientific & Technical Instr. peers over the last three months, over the past year it has lagged behind its peers.
Company DescriptionCardioGenics Holdings Inc., formerly JAG Media Holdings, Inc. is engaged in the development of products, targeting the immunoassay segment of the point-of-care (POC) in vitro diagnostic (IVD) testing market. The Company is focused on developing diagnostic test products to the IVD market. The Company's QL Care Analyzer (QLCA) is an automated point-of-care immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. Each cartridge is pre-loaded with the Company's beads, which have been coated with specific bind reagents and bioluminescent proteins linked to the target marker. A drop of whole blood added to the Cartridge creates the chemiluminescent reaction needed to deliver test results. It has developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. On July 31, 2009, it acquired CardioGenics Inc. (CardioGenics).
Growth
Investors need to know how much goods or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. In general, look for companies that sell and earn more than peers.
Net Profit Margin
293%
-137,131.00%-76,722%Insufficient data on CGNH for analysis of Net Profit Margin.
Earnings per Share Growth (TTM)
17,766%
-763.03%-961%EPS growth at CGNH is improving and is above the industry average. In addition there was no clear trend in EPS at CGNH over the last five years. The most recent EPS was -0.8327, a decrease of -763.03% over the previous year.
Sales Growth
8,313%
-2,200%Insufficient data on CGNH for analysis of Sales Growth.
Income Growth
2,717%
-2,038.03%-2,038%There was no clear trend in income growth at CGNH over the last five years.
Fundamentals
How is the company’s financial health?
When assessing the financial health of a company be aware that it is most relevant to compare the company against its peers as most ratios vary by industry. In addition, rarely will one ratio or statistic alone provide enough insight into the company to form and informed opinion.
Price/Earnings Ratio (TTM)
151.9x
0.2xInsufficient Price Earnings data on CGNH.
Price/Book (MRQ)
0.0x
14.8x1,087.0xLast quarter the Price to Book ratio at CGNH was 14.8x.
Return on Equity (TTM)
93%
-1,896%CGNH has a ROE of -114.99%
Total Debt/Total Capital (MRQ)
238%
0.00%0%CGNH uses little or no debt in its capital structure and may have less financial risk than the industry aggregate.
Provided by RBC
